Phase 1
Completed N=44
A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)
Source: ClinicalTrials.gov NCT00873821 ↗Enrolled (actual)
44
Serious AEs
0.0%
Results posted
Jul 2012
Primary outcomePrimary: Number of Participants With Any Clinical Adverse Experience — 18; 16 participants
Summary
A study to test the pharmacokinetics after twice daily administration of MK-0941 or placebo in subjects with type 2 diabetes who have inadequate control on metformin.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Any Clinical Adverse Experience |
18; 16 | — |
| PRIMARY Number of Participants With Any Laboratory Adverse Experience |
3; 1 | — |
| PRIMARY Change From Baseline to Day 13 in Weighted Mean Plasma Glucose Concentration |
196.4; 194.6; -56.4; -15.6 | <0.001 sig |
Eligibility Criteria
Inclusion Criteria
- Subject has a BMI 1500 mg metformin per day for at least 8 weeks
- Subject has HbA1c value of 7.0% and 3 alcoholic beverages per day
- Subject has had major surgery or has donated blood in the last 4 weeks
Data sourced from ClinicalTrials.gov (NCT00873821). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.